CN112601524A - 加波沙朵在治疗物质使用障碍中的用途 - Google Patents

加波沙朵在治疗物质使用障碍中的用途 Download PDF

Info

Publication number
CN112601524A
CN112601524A CN201980037011.8A CN201980037011A CN112601524A CN 112601524 A CN112601524 A CN 112601524A CN 201980037011 A CN201980037011 A CN 201980037011A CN 112601524 A CN112601524 A CN 112601524A
Authority
CN
China
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037011.8A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN112601524A publication Critical patent/CN112601524A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980037011.8A 2018-04-06 2019-04-06 加波沙朵在治疗物质使用障碍中的用途 Pending CN112601524A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862653641P 2018-04-06 2018-04-06
US62/653,641 2018-04-06
US201862654786P 2018-04-09 2018-04-09
US62/654,786 2018-04-09
PCT/US2019/026218 WO2019195813A1 (en) 2018-04-06 2019-04-06 Use of gaboxadol in the treatment of substance use disorders

Publications (1)

Publication Number Publication Date
CN112601524A true CN112601524A (zh) 2021-04-02

Family

ID=68101544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037011.8A Pending CN112601524A (zh) 2018-04-06 2019-04-06 加波沙朵在治疗物质使用障碍中的用途

Country Status (10)

Country Link
US (2) US20190321341A1 (https=)
EP (1) EP3761979A4 (https=)
JP (1) JP2021521103A (https=)
KR (1) KR20210039324A (https=)
CN (1) CN112601524A (https=)
AU (1) AU2019249277A1 (https=)
CA (1) CA3095682A1 (https=)
IL (1) IL277805A (https=)
MX (1) MX2020010545A (https=)
WO (1) WO2019195813A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008675A1 (en) * 1999-07-30 2001-02-08 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
US20020042446A1 (en) * 1998-08-05 2002-04-11 Dewey Stephen L. Treatment of addiction and addiction-related behavior
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
CN101156850A (zh) * 2003-06-25 2008-04-09 H.隆德贝克有限公司 抑郁症和其他情感障碍的治疗
CN101168056A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 混合物制剂
US20080207601A1 (en) * 2005-04-07 2008-08-28 Hythiam , Inc. Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence
CN103269699A (zh) * 2010-08-24 2013-08-28 加利福尼亚大学董事会 包括给予二氢杨梅素的治疗酒精中毒、酒精使用障碍以及酒精滥用的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
CN101168058A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 一种混合物制剂
CN101168057A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 多巴胺激动剂制剂
GB0810063D0 (en) * 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042446A1 (en) * 1998-08-05 2002-04-11 Dewey Stephen L. Treatment of addiction and addiction-related behavior
WO2001008675A1 (en) * 1999-07-30 2001-02-08 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
CN101156850A (zh) * 2003-06-25 2008-04-09 H.隆德贝克有限公司 抑郁症和其他情感障碍的治疗
US20080207601A1 (en) * 2005-04-07 2008-08-28 Hythiam , Inc. Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence
CN101168056A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 混合物制剂
CN103269699A (zh) * 2010-08-24 2013-08-28 加利福尼亚大学董事会 包括给予二氢杨梅素的治疗酒精中毒、酒精使用障碍以及酒精滥用的方法

Also Published As

Publication number Publication date
EP3761979A4 (en) 2021-06-30
MX2020010545A (es) 2021-01-08
KR20210039324A (ko) 2021-04-09
US20190321341A1 (en) 2019-10-24
US20220241253A1 (en) 2022-08-04
WO2019195813A1 (en) 2019-10-10
AU2019249277A1 (en) 2020-10-22
CA3095682A1 (en) 2019-10-10
JP2021521103A (ja) 2021-08-26
EP3761979A1 (en) 2021-01-13
IL277805A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US20250127712A1 (en) Compositions and methods for the treatment of opioid overdose
TWI486161B (zh) 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
HK1231370A1 (zh) 鼻用药物产品及其使用方法
US20220241253A1 (en) Use of gaboxadol in the treatment of substance use disorders
US20230225961A1 (en) Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
US20260021038A1 (en) Compositions and Methods for the Treatment of Opioid Overdose
KR20140014350A (ko) 정맥 내 투여용 이부프로펜의 투여
EP3793558A1 (en) Formulations and methods for the prevention of opioid overdose
AU2019253577B2 (en) Oxytocin compositions and methods of use
HK40050846A (en) Use of gaboxadol in the treatment of substance use disorders
CN113260362A (zh) 加波沙朵、加奈索酮和别孕烯醇酮用于治疗运动障碍的用途
KR20200022026A (ko) 치료 방법 및 이의 약형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050846

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210402

WD01 Invention patent application deemed withdrawn after publication